Medpage Today on MSN
Epilepsy Treatment Resistance May Fade Over Time
Longitudinal data suggested that treatment-resistant focal epilepsy may improve over time. Focal treatment-resistant epilepsy ...
TipRanks on MSN
ONO Pharmaceutical’s Phase III Study on Cenobamate: A Potential Game-Changer for Epilepsy Treatment
ONO Pharmaceutical Co (($OPHLF)) announced an update on their ongoing clinical study. Study Overview: ONO Pharmaceutical Co. Ltd is conducting a ...
Xenon Pharmaceuticals (($XENE)) announced an update on their ongoing clinical study. Study Overview: The clinical study titled A Multicenter, ...
Surgical intervention may offer substantial seizure reduction and functional benefits for individuals with ASD and drug-resistant epilepsy.
Focal treatment-resistant epilepsy improves over time, but seizure reduction appears to be unrelated to specific medications ...
About one-third of patients with focal epilepsy, a common form of the neurological disorder, are believed to respond poorly ...
The study assessed OV329 in 68 healthy subjects, comprising 51 individuals receiving active treatment and 17 receiving placebo.
The new study, part of the international Human Epilepsy Project, tracked nearly 150 adults who were deemed ...
News-Medical.Net on MSN
New study offers hope for patients with treatment-resistant focal epilepsy
About one-third of patients with focal epilepsy, a common form of the neurological disorder, are believed to respond poorly ...
Bright Minds Biosciences Inc. (NASDAQ:DRUG) has been able to initiate its phase 2 BREAKTHROUGH study using its 5-HT2C agonist BMB-101 for the treatment of adult patients with classic Absence Epilepsy ...
The Express Tribune on MSN
Epilepsy surgery effective treatment for drug-resistant patients: Dr Fowzia Siddiqui
Successful surgeries in Pakistan highlight early intervention and multidisciplinary care for drug-resistant epilepsy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback